Jonathan Rubin
Technik-/Wissenschafts-/F&E-Leiter bei SUPERNUS PHARMACEUTICALS, INC.
Vermögen: 2 Mio $ am 30.04.2024
Profil
Dr. Jonathan Rubin is a Senior VP-R&D, Chief Medical Officer at Supernus Pharmaceuticals, Inc. Dr. Rubin was previously employed as a Chief Medical Officer by Atentiv LLC, a Chief Medical Officer by Alcobra Ltd., a Director-Medical Clinical Development by Shire Pharmaceuticals, Inc., and a Medical Director by Shire Development LLC.
He received his undergraduate degree from Yale University, an MBA from Columbia Business School and a doctorate degree from The University of Connecticut School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ASHTROM GROUP LTD.
0,14% | 29.06.2023 | 144 849 ( 0,14% ) | 2 Mio $ | 30.04.2024 |
| 18.04.2024 | 4 641 ( 0,01% ) | 136 028 $ | 30.04.2024 |
Aktive Positionen von Jonathan Rubin
| Unternehmen | Position | Beginn |
|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
Ehemalige bekannte Positionen von Jonathan Rubin
| Unternehmen | Position | Ende |
|---|---|---|
Atentiv LLC
 Atentiv LLC Packaged SoftwareTechnology Services Atentiv LLC develops educational and digital learning tools. The company is based in Waltham, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2020 |
Alcobra Ltd.
 Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2017 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01.09.2017 |
| Shire Development LLC | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Jonathan Rubin
| Yale University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
| The University of Connecticut School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Health Technology |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
| Shire Development LLC | |
Atentiv LLC
Atentiv LLC Packaged SoftwareTechnology Services Atentiv LLC develops educational and digital learning tools. The company is based in Waltham, MA. | Technology Services |